Ganitumab Provides No Benefit in Metastatic Ewing Sarcoma
Adding ganitumab to standard chemotherapy does not provide a benefit for patients with metastatic Ewing sarcoma, a phase 3 trial suggests.
Diagnosis & Disease Information
Childhood, Adolescent Cancers Linked to Higher Risk of Major Psychiatric Disorders
Compared with the general population, survivors of childhood and adolescent cancers have an increased risk of 6 major psychiatric disorders.
Treatment Changes May Have Reduced Rates of Invasive Breast Cancer in Childhood Cancer Survivors
The incidence of invasive breast cancer among childhood cancer survivors decreased from the 1970s to the 1990s.
Adding Ifosfamide to MAP Provides No Benefit in High-Grade Osteosarcoma
Phase 3 data do not support adding ifosfamide to adjuvant methotrexate, doxorubicin, and cisplatin in patients with high-grade osteosarcoma.
Dinutuximab Plus GM-CSF Falls Short in Recurrent Osteosarcoma
Dinutuximab plus GM-CSF produced a low disease control rate that did not meet a historical benchmark.
Carboplatin Deemed Acceptable Replacement for Actinomycin-D in Ewing Sarcoma
There was no significant difference in overall survival between patients who received actinomycin-D and those who received carboplatin.
Standardized Treatment Eliminates Outcome Disparities in Non-Metastatic Osteosarcoma
Survival outcomes for patients on the EURAMOS-1 trial were not affected by race/ethnicity or poverty exposure.
High-Dose Ifosfamide Bests Topotecan-Cyclophosphamide in Relapsed/Refractory Ewing Sarcoma
Ifosfamide improved event-free and overall survival.
Persistent Opioid Use After Sarcoma Treatment Explored Among Youth
Twenty-three percent of adolescents and young adults with sarcoma who used opioids during treatment had new persistent opioid use after treatment.
Lurbinectedin Deemed “Valuable” Treatment Option for Relapsed Ewing Sarcoma
Lurbinectedin produced an overall response rate of 14.3% and a disease control rate of 57.1%.
- Loading...
Loading...
Next post in Bone Cancer
Loading... 
Loading...